Breast: Page 248

DBT not only finds more cancers, but more invasive ones
By Kate Madden Yee
In community practice, digital breast tomosynthesis (DBT) performed better than conventional 2D mammography, reducing recall rates, increasing overall cancer detection, and increasing the detection of invasive cancer, according to research published online June 11 in the American Journal of Roentgenology.
June 17, 2014
FDA readies new MQSA audits
By AuntMinnie.com staff writers
The U.S. Food and Drug Administration said that on June 23 it will begin an audit of certified mammography facilities that claim a Government Entity exemption under the Mammography Quality Standards Act (MQSA).
June 16, 2014
Mammo more effective when patient risk is considered
By AuntMinnie.com staff writers
Taking a woman's health risk profile into account can reduce the number of cancer instances missed and also cut the number of false positives, according to research presented at a conference of the Institute for Operations Research and the Management Sciences.
June 16, 2014
Breast tomosynthesis adoption uneven across the U.S.
By Kate Madden Yee
When used with digital mammography, digital breast tomosynthesis has been shown to improve the diagnostic accuracy of breast cancer screening and diagnosis. But exactly how and where is it being used in the U.S.? Researchers investigated this question and presented their findings in the June issue of the Journal of the American College of Radiology.
June 16, 2014
2014 06 16 13 22 21 141 United States Map 200
Synthesized 2D images dramatically reduce DBT radiation dose
By Kate Madden Yee
Breast imagers reading 2D images synthetically reconstructed from digital breast tomosynthesis (DBT) data had comparable performance to those reading conventional 2D mammography and DBT scans for breast cancer screening, while exposing women to less radiation dose, according to a study published in the June issue of Radiology.
June 12, 2014
2014 06 12 13 25 42 366 Skaane Figure2 400 20140612203203
FDA clears Bayer's Gadavist contrast for breast MRI
By AuntMinnie.com staff writers
The U.S. Food and Drug Administration has approved a new indication for Bayer HealthCare's Gadavist MRI contrast agent.
June 11, 2014
MDCT: Kalender offers update on breast CT
By Kate Madden Yee
Clinical trials for a high-resolution breast CT scanner will begin in Germany in early 2015, according to a talk by Willi Kalender, PhD, at the International Symposium on Multidetector-Row CT (MDCT). The hope is that the technology will outperform full-field digital mammography and breast tomosynthesis at equivalent dose levels.
June 11, 2014
2014 05 28 16 41 19 81 Golden Gate San Francisco 200
Cancer: Screening mammo cuts incidence of late-stage cancer
By Kate Madden Yee
Over the past 30 years, screening mammography has not only identified more early-stage breast cancer, it decreased the incidence of late-stage disease by more than a third, according to a study published online in the journal Cancer.
June 11, 2014
VuCOMP lands FDA nod for M-Vu CAD 3.1
By AuntMinnie.com staff writers
Computer-aided detection (CAD) firm VuCOMP has received U.S. Food and Drug Administration approval for mammography version 3.1 of its M-Vu CAD software.
June 10, 2014
SNMMI: Bigger, earlier dose of MBI agent finds more breast cancer
By AuntMinnie.com staff writers
A new molecular breast imaging (MBI) protocol can identify more metastasized cancer, according to research presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in St. Louis.
June 9, 2014
SNMMI: SPECT/CT shines at sentinel lymph-node imaging
By AuntMinnie.com staff writers
Presurgical SPECT/CT provides more effective sentinel node imaging than lymphoscintigraphy, according to results from an international multicenter trial presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting.
June 9, 2014
SNMMI: Molecular imaging offers hope for novel breast cancer treatments
By AuntMinnie.com staff writers
An antibody-based molecular imaging agent attacks a newly targeted breast cancer cell receptor, HER3, suggesting a potential new therapy for aggressive disease, according to research presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting.
June 8, 2014
Previous Page
Page 248 of 579
Next Page